drugset / Trial / NCT02245360

Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

NCT02245360 ↗

Phase 3 Completed 107 enrolled Abbott
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the immunologic effects and safety of 60-day treatment of the Standardized Quality units (SQ) grass Sublingual immunotherapy (SLIT)-tablet in adult subjects with grass pollen-induced allergic rhinoconjunctivitis in a double-blind, placebo-controlled study.

Timeline

Start
2014-10
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Phleum pratense grass pollen allergen extract Unknown 75000 unknown Other